ATLAS Biolabs and Ingenuity® Systems Sign Collaboration Agreement
News Jun 20, 2012
ATLAS Biolabs and Ingenuity® Systems have signed a collaboration agreement that gives customers of ATLAS Biolabs the option to analyze and interpret their study data using Ingenuity solutions.
Ingenuity Variant Analysis will be used to identify causal variants from the output of whole genome and exome sequencing experiments and iReport will be used for the biological interpretation of RNA-Seq and other gene expression data.
Both solutions leverage the Ingenuity Knowledge Base, a repository of biological interactions and functional annotations created from millions of individually modelled relationships between proteins, genes, complexes, cells, tissues, metabolites, drugs, and diseases.
By offering the Ingenuity products, ATLAS Biolabs supports the complete workflow from project design to scientific analysis, providing its customers with high quality laboratory and bioinformatic services.
“The Ingenuity products facilitate and accelerate the bioinformatics support we provide to our customers. They allow us and our customer to interactively manoeuvre through the data and shed light on it from multiple biological perspectives, to understand the biological meaning.” explains Dr. Karsten R. Heidtke, Head of Bioinformatics at ATLAS Biolabs.
“We are very pleased to partner with ATLAS Biolabs in Europe to offer a complete “sample to insight” solution to ATLAS Biolabs’ customers combining ATLAS Biolabs’ lab services with Ingenuity’s analysis and biological interpretation solution,” stated Sean Scott, Sr. Vice President, Global Commercial Operations, Ingenuity Systems.
Scott continued, “By providing Ingenuity iReport and Ingenuity Variant Analysis, ATLAS Biolabs can support researchers working with RNA-Seq and DNA resequencing data, so that they can quickly and reliably understand the underlying biology of their experiments.”
Phenogenetic Map Created For Stem Cell Models Of Neurological DiseasesNews
Researchers at The Ohio State University Wexner Medical Center have performed the first meta-analysis of all induced pluripotent stem cell models for neurological and neurodegenerative diseases, and created an atlas of how cell characteristics are linked to their genotype.READ MORE
Fabric Genomics Partners to Improve Pediatric CareNews
Partnerships with Genomics England, Rady Children's Institute for Genomic Medicine, and The Utah Genome Project demonstrate diagnostic utility of Fabric Genomics' algorithm-based genome analysis.READ MORE
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE